Welcome to our dedicated page for Core Laboratories SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Core Laboratories Inc. (CLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Core Laboratories is listed on the New York Stock Exchange under the symbol CLB, and its filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe its financial condition, capital structure, and material events.
Recent 8-K filings referenced by the company include disclosures of quarterly financial results, dividend declarations, and a Ninth Amended and Restated Credit Agreement. That agreement increased the aggregate borrowing commitment, extended the maturity date of the credit facility, and outlined conditions related to outstanding senior notes, while noting that there were no material changes to other key terms such as collateral, pricing, and financial covenants.
Through this page, users can review Core Laboratories’ periodic reports to understand segment performance in Reservoir Description and Production Enhancement, management’s discussion of free cash flow and leverage, and details on capital allocation decisions such as share repurchases and dividends. Current reports on Form 8-K also document events like earnings releases, changes to credit arrangements, and other significant corporate actions.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify information about revenue trends, liquidity, debt facilities, and board-approved dividends. Users can also track updates related to credit agreements and other obligations described in filings, alongside real-time access to new submissions as they appear in the SEC’s EDGAR system.
Core Laboratories director Curt Anastasio reported routine equity compensation activity involving restricted shares and common stock. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance.
These Restricted Shares are subject to a deferral election under Treasury Regulation 1.409A-2, with vested shares to be distributed as common stock following his separation of service from the Board. He also exercised 8,069 Restricted Shares that had vested after a one-year vesting period ending April 1, 2026, receiving 8,069 shares of Common Stock and bringing his directly held common shares to 23,805. The filing shows acquisitions and exercises only, with no open-market buying or selling.
Core Laboratories Inc. director Harvey Robert Klingensmith reported equity compensation activity in company stock. He received a grant of 7,895 Restricted Shares on April 1, 2026 at a price of $0.00 per share. According to the terms, these Restricted Shares will vest at the end of a one-year vesting period on April 1, 2027, and are subject to a deferral election, with vested shares distributed as common stock after his separation of service from the Board. On the same date, 8,069 previously granted Restricted Shares vested at the end of their one-year vesting period and were converted into 8,069 shares of Common Stock at $0.00 per share. Following these transactions, Klingensmith directly holds 50,031 shares of Core Laboratories common stock.
Core Laboratories director Temeng Kwaku reported equity compensation and an option-style exercise. On April 1, 2026, he received a grant of 7,895 Restricted Shares that will vest after a one-year period ending on April 1, 2027, subject to the terms of issuance and a deferral election under Treasury Regulation 1.409A-2.
The filing also shows 8,069 Restricted Shares vested after a one-year period ending April 1, 2026 and were exercised into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, Kwaku directly holds 33,597 shares of Core Laboratories Common Stock.
Core Laboratories Inc. director Robert F. Martinovich reported equity-based compensation activity. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance and any deferral election.
Separately, 8,069 Restricted Shares vested at the end of a prior one-year vesting period on April 1, 2026 and were exercised into 8,069 shares of Common Stock, which he now holds directly. The filing shows only awards and an option-style conversion of restricted equity into common stock, with no open-market purchases or sales.
Core Laboratories director Martha Z. Carnes reported equity compensation activity involving restricted shares and common stock. She received a grant of 7,895 Restricted Shares on April 1, 2026, which will vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance.
On the same date, 8,069 previously granted Restricted Shares completed their one-year vesting period ending April 1, 2026 and were converted into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, she directly holds 54,397 shares of Core Laboratories common stock.
Core Laboratories Inc. is asking shareholders to vote at its May 12, 2026 annual meeting on four items: re‑electing two Class I directors until 2029, ratifying KPMG LLP as auditor for 2026, approving on an advisory basis executive compensation, and handling any other proper business.
Shareholders of record at the close of business on March 18, 2026, when 46,048,268 common shares were outstanding, are entitled to one vote per share. The proxy describes a classified, majority‑independent board, detailed committee structure, and a pay program that is heavily performance‑based, with 100% of named executive officer long‑term incentives in performance share units tied primarily to return on invested capital and relative financial metrics.
The company highlights 2025 business results including operating margin of 10.7%, an estimated 9.8% return on invested capital relative to peers, and strong safety performance, and notes that 94.3% of votes cast in 2025 supported its executive pay program.
The Vanguard Group filed Amendment No. 4 to its Schedule 13G/A reporting 0 shares of Core Laboratories Inc. common stock. The filing states Vanguard's subsidiaries underwent an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The amendment shows Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
Core Laboratories Inc. updated its outlook for first quarter 2026, warning that revenue and earnings will fall below guidance issued on February 4, 2026 due to the escalating Middle East conflict. The company now expects revenue between $119,000,000 and $123,000,000, with operating income ex-items of $5,700,000 to $7,100,000. Earnings per share ex-items are projected at $0.05 to $0.07. Client-driven project delays, travel constraints, supply-chain disruptions and damage to regional oil infrastructure are pressuring activity, especially in Reservoir Description, while Production Enhancement is less affected but facing shipment delays. Core plans to discuss results on an April 30, 2026 earnings call following an April 29, 2026 release.
Core Laboratories Inc. provides specialized reservoir description and production enhancement services to oil and gas companies worldwide. The company operates in more than 50 countries with about 3,300 employees, and reported consolidated revenue of $526,520,000 for the year ended December 31, 2025, primarily from services rather than products.
Two main segments drive results: Reservoir Description, focused on rock and fluid analysis and digital reservoir characterization, and Production Enhancement, which supplies perforating systems and diagnostics to optimize well completions and enhanced recovery. Core Lab is increasingly involved in carbon capture and storage and other energy transition projects, while remaining heavily exposed to oil and gas spending cycles.
The report highlights extensive risk factors, including industry cyclicality, geopolitical instability in regions such as the Middle East and Russia/Ukraine, evolving sanctions regimes, climate and environmental regulation, cybersecurity threats, supply chain concentration, and challenges in attracting technical talent. A significant portion of revenue is generated outside the United States, adding currency and regulatory risk alongside growth opportunities.
Core Laboratories Inc. is filing an amended current report to correct income tax accounting in its previously released 2025 results. Estimated income tax expense for the quarter and year ended December 31, 2025 increased by $4.2 million, reducing net income by the same amount and lowering diluted earnings per share by $0.09 per share. The change stems mainly from updated analyses of deferred tax assets and liabilities and the tax treatment of insurance proceeds from a fire at the company’s Aberdeen, U.K. facility. Core also corrected immaterial prior-period items, including a $5.6 million write-off of older income tax receivables and a $4.7 million misclassification between income tax receivable and deferred tax liabilities. The company states these tax adjustments do not affect consolidated revenue, operating income, income before tax, or cash from operations previously reported in its earnings release.